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To investigate the possible link between Porphyromonas gingivalis (P. gingivalis) infection 
and RA, according to antibody profile, genetic and environmental factors, and RA severity. 
 
Patients and Methods 
For assessing P. gingivalis infection, serum levels of antibodies directed against P. gingivalis 
LPS were measured in 694 early-RA patients not exposed to steroid or DMARD. Anti-P. 
gingivalis antibodies titers were compared between early-RA patients and various control 
groups, and according to various patients characteristics.  
 
Results 
The titre of anti-P. gingivalis antibodies did not significantly differ between RA and controls. 
Anti-P. gingivalis antibody titres did not significantly differ with ACPA, RF, or HLA-shared 
epitope status. Anti-P. gingivalis antibody titres were significantly higher among never 
smoker patients compared to ever-smoker (p= 0.0049). Among non-smokers, high anti-P. 
gingivalis antibody levels were associated with an higher prevalence of erosive change 
(mSHS erosion subscale ≥1 : 47.5 vs. 33.3%, p=0.0135). 
 
Conclusion 
In this large early-RA cohort, we did not detect any association of anti-P. gingivalis 
antibodies with RA or with ACPA status. These results suggest that the association of 
periodontitis and RA could be linked to other bacterial species than P. gingivalis or to 
another mechanism than citrullination. Nevertheless we found higher anti-P. gingivalis 
antibody titres in non-smokers. In addition, in this population of non-smokers, high anti-P. 
gingivalis antibody titres were associated with a more severe disease. We hypothesize that 
the role of tobacco in RA pathogenesis is so high that the effect of P. gingivalis could be 
revealed only in a population not exposed to tobacco. 
 
Rheumatoid arthritis (RA) is a systemic, inflammatory autoimmune disorder of unknown, 
complex and multifactorial aetiology. Its pathophysiology relies on an interaction between 
gene and environment that triggers auto-immunity. One of the most striking examples is the 
interaction between tobacco and shared epitope carrying in anti-citrillinated peptide 
antibody (ACPA) positive RA [1]. In this model, tobacco acts as an external agent inducing 
citrullination of proteins in the lung that triggers auto-immunity and ACPA production in 
genetically predisposed subjects, leading to emergence of RA. 
Among the other potential environmental factors triggering auto-immunity is the oral 
microbiome. Several epidemiological studies have suggested a link between periodontal 
disease and RA. The prevalence of periodontal disease is two-fold increased among patients 
with RA compared to the general population[2-4], and even more in non-smoking RA 
patients with a 4-fold increased prevalence[5].  In addition, several cohorts have shown that 
the risk of development of RA was increased in subjects with periodontal disease [6-8].This 
risk was even more important in non-smokers [4, 8]. 
One of the main bacteria implicated in chronic periodontal disease is Porphyromas (P) 
gingivalis [9], a microorganism of the oral cavity located in the sub-gingival tissue. P. 
gingivalis has been incriminated in RA pathogenesis because it is one of the few 
microorganisms with a deiminase capable of transforming arginine into citrulline, and is thus 
suspected of playing a possible role in the production of ACPA. Some recent studies suggest 
that the presence of P. gingivalis could be associated with development of RA [10-13] and 
particularly ACPA-positive RA [10, 11, 13-15]. Nevertheless, these results remain 
controversial [4, 16] and were obtained for most of them from small cohorts.  
The objective of this study was to investigate the relationship between P. gingivalis infection 
(as measured by serum levels of anti-P. gingivalis antibodies) and RA. This study also aimed 
to investigate the possible link between P. gingivalis infection and RA antibody profile 
(principally ACPA status), genetic and environmental factors and structural damage in a large 
cohort of early arthritis patients. 
PATIENTS AND METHODS 
Patients 
The Evaluation et Suivi des POlyarthrites Indifférenciées Récentes (ESPOIR) is a prospective 
French cohort that included 813 patients with early arthritis. The methodology and the main 
characteristics of the patients from the ESPOIR cohort have been previously described [17]. 
The patients were recruited if they had inflammatory arthritis of at least 2 swollen joints 
lasting for 6 weeks to 6 months and with potential to evolve into RA. Patients were included 
if they had not received disease-modifying anti-rheumatic drugs (DMARDs) (except within 
the 15 days before inclusion in the cohort for DMARDs exclusively) or steroids. Patients were 
excluded if the referring physician considered another defined inflammatory rheumatic 
disease than RA. The patients were included between December 2002 and March 2005. They 
have been followed every 6 months during the first 2 years, and every year thereafter. The 
follow-up is scheduled for at least 15 years from December 2002.  Among them, 694 fulfilled 
the 2010 ACR/EULAR criteria after 2 years of follow-up. Fourteen regional centres in France 
participated in patients’ inclusion.  
Clinical and biological assessment 
Clinical variables included total joint count for tenderness and swelling, the Disease Activity 
Score in 28-joints (DAS28)[18] and the Health Assessment Questionnaire (HAQ)[19]. 
Laboratory variables included erythrocyte sedimentation rate (ESR, mm/h), C-reactive 
protein (CRP) level, IgM and IgA rheumatoid factor (RF) (both enzyme-linked immunosorbent 
assay [ELISA; Menarini], both positive if > 9 UI/ml), ACPA (anti-CCP2, ELISA, DiaSorin, France; 
positive if > 50 U/ml). All the subjects were genotyped for the HLA-DRB1 shared epitope (SE). 
Pro-inflammatory cytokines (Interleukin (IL)-1β, IL-1 receptor antagonist (IL1-Ra), IL-2, IL-4, 
IL-6, IL-10, IL-17, MCP-1, Tumor Necrosis Factor (TNF) α and interferon (IFN) γ were 
previously quantified in ESPOIR cohort at baseline using a commercially available multiplex 
bead immunoassay, based on the Luminex platform (Fluorokine MAP Multiplex Human 
Cytokine Panel, R&D Systems, Minneapolis, Minnesota, USA) as previously described 
[20].The corresponding quantifications are expressed in ng/ml. The method of quantification 
of serum markers of B cell activation (β2-microglobulin, IgG, IgA, IgM, Free light chain of 
immunoglobulins [FLCs]) were previously reported [21]. 
Smoking history 
Patients’ smoking habits were evaluated at inclusion. Current smokers were those reporting 
active smoking. Past-smokers were all patients who had stopped smoking before the first 
examination at inclusion. Ever-smoker included both current and past-smokers. Non-




Patients had radiological evaluation every 6 months during the first two years of follow-up 
allowing studying parameters associated with structural progression. Radiographs of the 
hands and feet (antero-posterior views) were collected in the radiography coordinating 
centre. A standardized reading was performed on X-rays obtained at baseline, 1 year and 2 
years of follow-up. All sets of X-rays were read by a trained investigator blinded to clinical 
evaluation (GT) according to the van der Heijde-modified total Sharp score (mSHS). Intra-
reader and inter reader reliability (GT and VD-P) were excellent (Intraclass correlation 
coefficient = 0.97 and 0.93, respectively). The smallest detectable change (SDC) was 1 [22]. 
Structural damage at inclusion was assessed qualitatively by the presence of typical RA 
erosions according to their location and aspect, and was rated according to mSHS[23]. 
Radiological progression was assessed between baseline and the end of the second year of 
follow-up. Radiological progression was defined as a progression of more than the SDC (≥1 
point of mShS) at 2 years. Rapid Radiological Progression (RRP) was defined as an increase of 




Variété is a transversal, non-interventional French national cohort, based on healthy 
volunteers for establishing normative data for IGF-I and other hormones in the general 
population (ClinicalTrials.gov identifier: NCT01831648). A total of 974 healthy subjects have 
been recruited in 10 centres all around France. Subjects with medical conditions and 
medications that may affect IGF-I measurement have been excluded. A random sample of 79 
healthy controls from the Variété cohort was matched, for age- and gender, to a 
representative sample of 79 RA patients from ESPOIR cohort. Since this cohort focused on 
healthy subjects with no risk factors, it included only non-current smokers: among them, 
83.7% were never-smokers and the remaining 16.2% did not smoke more than 10 
cigarettes/day.  
Sicca Controls 
Sicca controls were 54 patients form the cohort of patients with sicca symptoms referred to 
the Rheumatology Department of the Bicêtre Hospital for a diagnostic procedure to assess if 
patients have Sjögren's syndrome. To be considered as controls patients, these subjects 
were excluded if they had auto-antibodies, lymphocytic sialadenitis on salivary gland biopsy 
or any features of auto-immunity. Nevertheless, some of them had objective dryness 
features. These controls were age- and gender-matched to a random sample of RA patients 
from ESPOIR cohort. Their smoking status was known as never or ever smoker, with no 
mention of current or past smoking status. This group included 19/51 (37.3%) ever smokers. 
Periodontitis controls 
The last control group consisted in 61 patients with clinically proven severe periodontitis. In 
this group, 21 (34.5%) patients were non-smokers, 40 (65.6%) were ever smokers, including 
13 (21.3%) current smokers. These patients were not matched with ESPOIR cohort patients, 
and included a higher proportion of males. We therefore took a matched subsample of this 
group having a same proportion of male as the RA cohort to perform sensitivity analyses for 
comparisons with early RA patients. In addition, for this group of patient, Micro-Indent test 
was performed to detect the presence of P. gingivalis in periodontal tissue (see below). 
Bacterial serologic measurement and detection of P. gingivalis 
Anti-P. gingivalis antibodies measurement 
Immunoglobulin G antibodies specific to LPS of P. gingivalis were measured using a 
homemade ELISA. The wells of 96-well flat-bottom microtiter plates were coated in triplicate 
with LPS of P. gingivalis. After washing and blocking the plates, serum samples were added 
to individual wells and specific human IgG antibodies were detected with an alkaline 
phosphatase-conjugated antihuman immunoglobulin. The absorbance was read at 405 nm 
using an ELISA plate reader. The results were expressed as an ELISA index (EI), which was the 
mean OD 405 nm of a given serum divided by the mean OD 405 nm of the calibrator 
(reference serum) [11].  
Bacteria identification (DNA-DNA hybridation) 
Bacteria identification was made in the gingival pockets, with the kit Micro-Ident according 
to the manufacturer’s instructions (Hain Lifescience, Germany), as follows. DNA–DNA 
hybridization is a molecular biology technique that measures the degree of genetic similarity 
between pools of DNA sequences; it can be used to identify different species in a 
pluribacterial sample. In our case DNA was isolated from gingival pockets, amplified with 
specific primers (supplied in the kit; HainLifescience, Germany). In the next step, the 
amplicons were chemically denatured, since detection on the strip was done using single-
stranded DNA. The strip was coated with highly specific probes which were complementary 
to selectively amplified nucleic acid sequences. The single-stranded amplicon binds 
specifically to the analog probes during hybridization, while non-specifically bound 
amplicons were removed in subsequent washing steps. During the conjugate reaction, the 
specifically bound amplicon was marked with the enzyme alkaline phosphatase and was 
then made visible in a colorimetric detection reaction. 
Ethics 
The protocols of the ESPOIR cohort study and of the Variété cohort study were approved by 
the Ethics Committees of Montpellier University Hospital, and Hôpitaux Paris-Sud, France, 
respectively. All patients from ESPOIR and Variété Cohorts as well as sicca controls included 
in the present study gave their written informed consent. 
Statistical analyses 
All analyses were restricted to the subgroup of 694 patients fulfilling the ACR/EULAR criteria. 
Categorical variables are reported as numbers (percentages) and were compared using a χ² 
or, when appropriate, Fischer’s exact test. Quantitative variables are reported as mean (± 
standard deviation [SD]) and were compared using a Student t-test. For correlations 
analyses, Spearman’s correlation coefficients were obtained. 
Since results were not normally distributed, anti-P. gingivalis antibody titres were log-
transformed.  Also, anti-P. gingivalis titres were used as dichotomous variable. For that 
purpose, high titres were defined as a titre above the 75th percentile (upper quartile) of 
distribution in the RA patients of the ESPOIR cohort. 
 
To assess if anti-P. gingivalis antibodies titres were associated with early RA, titres were 
compared between RA patients and the different control groups. 
To identify parameters associated with anti-P. gingivalis antibodies titres, their serum levels 
were compared according various demographic, clinical characteristics, 
biological/biochemical and radiological variables (for categorical variables) and correlated 
with the levels of clinical, biological and radiological variables (for quantitative parameters). 
 
For all analyses, a p<0.05 was considered statistically significant. Confidence intervals were 
calculated at the 95% level. Statistical analyses involved use of SAS 9.3 (SAS Inst., Cary, NC). 
 
RESULTS 
Patients with early RA and controls 
Among patients from the ESPOIR cohort, 694 fulfilled the ACR/EULAR criteria for RA after 2 
years of follow-up. Their main characteristics are presented in Table 1. Age, sex and smoking 
status of early RA and controls groups are reported in Table 2.  
Anti-P. gingivalis antibody titres among controls and early RA patients 
Anti-P. gingivalis antibody titres did not significantly differ between early RA patients and 
healthy controls (1.47 ± 0.42 vs. 1.49 ± 0.33, p=0.66), sicca controls (1.47 ± 0.42 vs. 1.51 ± 
0.47, p=0.53) or periodontitis controls (1.47 ± 0.42 vs. 1.55 ± 0.41, p=0.17) (figure 1). Among 
periodontitis controls, the level of anti-P. gingivalis antibodies tended to be higher among 
females but this did not reach significance (1.54 ± 0.35 vs. 1.62 ± 0.47, p=0.28). We therefore 
compared the level of anti- anti-P. gingivalis antibodies between early RA and the sex-
matched subsample of periodontitis controls and found a trend to an higher level in 
periodontitis controls (1.47 ± 0.42 vs. 1.60 ± 0.44, p=0.12).  In addition, among periodontitis 
controls, 24 (39.34%) had P. gingivalis detected in periodontal tissue, these patients had a 
higher level of P. gingivalis antibodies, compared to periodontitis patients for whom P. 
gingivalis was not detected (1.74 vs. 1.43; p=0.008, figure 2). Thus, a high titre of anti-P. 
gingivalis is a good indirect marker of chronic P. gingivalis infection.  
Anti-P. gingivalis antibody titres among different subsets of early RA patients 
Anti-P. gingivalis antibody titres did not significantly differ with ACPA, RF, or HLA- shared 
epitope status (figure 3). Among ACPA positive patients, the level of anti-P. gingivalis 
antibody titres did not correlate with the level of ACPA (rho= 0.042, p=0.46), or RF titres 
(rho=0.013, p=0.82). Also, they did not correlate with disease activity (DAS28 or its 
components), pro-inflammatory cytokine levels, serum levels of B cell activation markers 
(β2-microglobulin, IgG, IgA, IgM, FLCs) or structural damage as measured by the total mShS 
and its subscales. However, patients with high anti-P.gingivalis antibody levels were more 
likely to have typical erosion related to RA than those with lower values (35/164 [21.34%] vs. 
69/497 [13.88%], p=0.02). Also, 40.1% (65/162) of the patients with high anti-P.gingivalis 
antibody titres had erosive RA (as measured by an mShS erosion subscale ≥ 1) compared to 
34.9% (173/496) of the patients with lowers titres (p=0.23. figure 4). 
 
Higher anti-P. gingivalis antibody titres in never smokers 
Anti-P. gingivalis antibody titres were significantly lower among ever-smoker patients 
compared to never smoker (1.42 ± 0.43vs. 1.51 ± 0.43, p= 0.0049) and particularly in current 
smoker patients compared to never smoker (1.37 ± 0.42 vs.1.51 ± 0.43, p= 0.0003), but not 
past-smokers (1.51 ± 0.43 vs. 1.47 ± 0.43, p= 0.28). Also, patients with high anti-P. gingivalis 
antibody titres were more likely to be non-smoker than those with low titres (107/175 
[61.1%] vs. 254/265 [48.9%], p=0.005).  
In the control groups, there was a numerical, but not significant, higher level of anti-P. 
gingivalis antibodies in never smokers compared to ever smokers in the sicca group (1.56 ± 
0.47 vs. 1.46 ± 0.48, p=0.45), and compared to current smokers in the periodontitis group  
(1.57 ± 0.48 vs. 1.48 ± 0.33, p=0.54).  
Among RA patients, smoking status did not alter the level of other antibodies (anti-CCP, IgM-
RF, FLC, total IgG, IgA, IgM), except the level of IgA-RF that were found significantly higher in 
smokers than in non smokers (45.6 UI ± 107.5 vs 29.1 ± 60.4; p=0.014).  
 
Higher anti-P. gingivalis antibody titres in non-smokers were associated with a more 
severe disease 
Among non-smokers, patients with high anti-P. gingivalis antibody levels were more likely to 
have erosive disease than those with lower titres as demonstrated by a higher proportion of 
patients having typical erosion related to RA (22/102 [21.6%] vs. 32/241 [13.3%], p=0.054) 
and having a mShS erosion subscale  ≥ 1 at baseline (48/101 [47.5%] vs. 80/240 [33.3%], 
p=0.014). This trend was not observed in the ever smoker group, neither past nor current 
smokers (figure 5). In the current smoker group, we observe an inverse but not significant 
relationship (p=0.20). However, anti-P. gingivalis antibodies titres were not predictive of 




This study is one of the largest that examined the possible link between P. gingivalis 
infection and RA, with a particular focus on RA-antibody profile (principally ACPA status), 
genetic and environmental risk factors and structural damage. In this cohort of early RA 
patients, we could not detect any association between anti-P. gingivalis antibodies and RA 
whatever the ACPA status. Nevertheless, we found that anti-P. gingivalis antibody titres 
were increased in never smokers. In this group of never smoker patients, increased levels of 
anti-P. gingivalis antibody were associated with a more erosive disease. 
We did not find higher anti-P. gingivalis antibody titres in RA patients compared to non-RA 
controls. There is to date no consensual method for dosing anti-P. gingivalis antibodies and 
each of them may be questionable. We here used an assay that detected antibodies to 
P. gingivalis LPS [16], rather than lysate or purified proteins used in some previous studies 
[10, 14, 15]. A method similar to that we used demonstrated such association with RA in a 
previous study [11]. Moreover, we found higher antibody titres in our positive control group, 
i.e. patients with P. gingivalis-associated periodontitis. Thus, our method seems to be valid 
for assessing a long-term exposure to P. gingivalis. Nevertheless, as shown by Scher et al, 
the presence of anti-P. gingivalis antibody is not necessarily associated with the presence of 
a currently active P. gingivalis infection. Therefore, none of these methods, including our, is 
able to detect current P. gingivalis infection, but they assess prior exposure to this pathogen. 
The only method able to prove P. gingivalis infection is the direct detection of the bacteria. 
Unfortunately, we did not have the opportunity to assess this in the ESPOIR cohort. At the 
time of the conception of this cohort, the implication of oral microbiome in RA pathogenesis 
was not suspected yet. Nevertheless, it is the largest cohort, involving almost 700 patients, 
exploring exposure to P. gingivalis in early RA. Compared with most of the previous studies, 
we here included early RA patients and not long standing established RA. Results of the 
previous studies assessing P. gingivalis infection in early RA are controversial [4, 13] and two 
recent studies did not also find any association between anti-P. gingivalis antibodies and RA 
[4, 16], particularly in the absence of proven periodontitis[16]. 
This study did not refute the potential role of oral microbiome in RA. First, the association 
between periodontitis and RA found in many studies, and confirmed in a recent systematic 
review [24], may be linked to another pathogen than P. gingivalis as recently suggested by 
Scher et al [4]. Second, tobacco plays such a major role in triggering RA that it may overtake 
and mask the potential role of P. gingivalis in smoker population. The role of P. gingivalis and 
other oral bacterial species could be revealed only in a population not exposed to tobacco. 
Effectively, the increased prevalence of periodontitis in non-smoker RA patients suggested in 
2 previous studies, underlined that the link between periodontitis, oral microbiome and RA 
could be more pronounced in the non-smoking population  [4, 8]. Last, even if P. gingivalis 
plays a major role, it may be by another mechanism than inducing citrullination since in 
number of studies including ours, there is no difference of anti-P. gingivalis titres in patients 
with or without ACPA. It could be also linked to the use of an anti-CCP2 kit that detects IgG 
but not IgA isotypes, the latter being possibly more associated to mucosa-associated 
antibody production. Nevertheless, other reports which found an association between P. 
gingivalis and ACPA status used similar assays [10, 15]. Although controversial [25], it has 
been recently found that auto-citrullination of P. gingivalis peptidylarginine deiminase 
(PPAD), is probably not the underlying mechanism linking P. gingivalis-associated 
periodontitis and RA [26]. Moreover, in 2 recent studies, it has been found that patients with 
periodontitis or with pre symptomatic RA have a higher titre of antibodies against 
uncitrullinated antigens suggesting that breaking of tolerance to uncitrullinated peptides 
could be the first event in these patients [27, 28] . Even more interestingly, in patients with 
periodontitis, the titres of antibodies against uncitrullinated antigens were more elevated in 
non-smokers than in smokers suggesting that the non-citrulline specific breaking of 
tolerance associated with periodontitis was even more important in non-smokers [28]. Also, 
in RA patients with periodontitis, smoking status did not influence ACPA titres, but had an 
impact on anti-P. gingivalis titres that were found lower in smokers than in non-smokers 
[29]. This observation clearly fits with our findings of a possible link between P. gingivalis 
infection and RA and severity of RA only in non-smokers. An alternative hypothesis would be 
a protective effect of smoking specifically on anti-P. gingivalis antibody generation, without 
any general effect on antibody or auto-antibody generation.  
 
In conclusion, we did not detect any association between anti-P. gingivalis antibodies and RA 
or ACPA status in this large cohort of early-RA. These results suggest that the association of 
periodonditis and RA could be linked to other bacterial species than P. gingivalis or to 
another mechanism than citrullination. Nevertheless we found higher anti-P. gingivalis 
antibody titres in non-smokers compared to smokers. In addition, in this population of non-
smokers, high anti-P. gingivalis antibody titres were associated with a more severe disease. 
We hypothesize that the role of tobacco in RA pathogenesis is so high that the role of P. 
gingivalis could be revealed only in a population not exposed to tobacco. Alternatively, 
smoking might decrease anti-P. gingivalis immune response. Finally, our findings suggest 
that the association of periodontitis and RA could be linked to other bacterial species than P. 
gingivalis or to another mechanism than citrullination and reinforce the importance of 
investigating the potential interest of oral hygiene and supragingival scaling in RA patients, 
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 Table 1. Characteristics of early-RA patients form the ESPOIR cohort 
 
 RA patients 
N= 694 
Sex (female) 543 (78.2%) 
Age (years) 48.5 ± 12.3 
Symptom duration (days) 74.8 ± 76.6 
BMI (kg/m²) 25.1 ± 4.6 
Ever smoker 333 (48.0%) 
   Current smokers 151 (21.8%) 
   Past smokers 182 (26.2%) 
CRP (mg/dl) 22.8 ± 34.7 
CRP us (mg/dl) 20.9 ± 33.5 
ESR (mm) 29.9 ± 24.8 
PGA (/100mm) 61.7 ± 24.6 
Tender joint count (/28) 9.4 ± 7.1 
Swollen joint count (/28) 7.9 ± 5.4 
DAS28 5.3 ± 1.2 
Anti-CCP 315 (45.4%) 
IgM-RF 372 (53.6%) 
Anti-CCP and/or RF (IgM or IgA) 438 (63.1%) 
Typical RA erosive change 181 (32.9%) 
Modified Sharp score 5.2 ± 7.4 
Current use of DMARD 48 (6.9%) 
Current use of oral corticosteroids  0 (0.0%) 
Current use of oral NSAIDs  487 (70.2%) 
Anti-P. gingivalis antibody titre 3.80 ± 2.23 
Anti-P. gingivalis antibody titre (logtransfromed) 1.47 ± 0.43 









Age (years) 48.5 ± 12.3 47.6 ± 11.9 48.9 ± 11.5 50,7± 8,3 
Sexe (female) 543 (78.2%) 66 (84.6%) 46 (85.2%) 25 (41.0 %) 
Ever smoker 333 (48.0%) 13 (16.2%)* 19/51 (37.3%) 40 (65.6%) 
* All past smokers
Figure 1. Anti-Porphyromonas gingivalis antibody titres in early-RA patients and various control groups 
Figure 2. Anti-Porphyromonas gingivalis antibody titres in periodontitis controls according to detection of Porphyromonas gingivalis in 
periodontal tissue 
P. gingivalis +: presence of Porphyromonas gingivalis in periodontal tissue samples; P. gingivalis -: absence of Porphyromonas gingivalis in 
periodontal tissue samples. 
Figure 3. Anti-Porphyromonas gingivalis antibody titres according to ACPA (A), HLA-SE (B) and erosive change (C) in early-RA patients 
ACPA: anti-citrullinated peptides antibody; HLA-SE: HLA shared epitope; mShS: van der Heijde-modified total Sharp score 
Figure 4. Link between anti-Porphyromonas gingivalis antibody titres, erosive changes according to smoking status in early-RA patients 
(A): Comparisons of anti-Porphyromonas gingivalis antibody titres according to smoking status 
(B): Link between anti-Porphyromonas gingivalis antibody and presence of erosive changes according to smoking status in early-RA patients. 
Percentage of patients with erosive RA (defined by an mShS erosion subscale ≥ 1) in patients with high anti-P.gingivalis antibody titres ≥75th 
percentile (dark grey) and in those with low anti-P. gingivalis antibody titres (light grey) according to smoking status. 
*: p=0,014 
